On Monday, September 12th, 11:00, Chordate's CEO Anders Weilandt will participate on Aktiespararnas event Aktiedagen Stockholm. He will mainly talk about the subgroup result of the migraine study PM007 on the K.O.S treatment that was presented in London on September 8, and what it means for the company. The subgroup result shows a statistically significant reduction in the number of headache days.
“This event will be a good opportunity for me to explain the very positive result from the subgroup analysis, how it should be interpreted and what it means for the company going forward”, says Anders Weilandt, Chordate CEO.
Aktiedagen takes place at Hotel Birger Jarl in Stockholm. To attend on site, register here. The event is streamed live at www.aktiespararna.se/tv/live and on Aktiespararna’s Youtube channel. No registration is required to follow the event digitally.
After the presentation, Anders Weilandt will participate in a Q&A and questions can be asked by sending an SMS to +46 79-347 98 45 or an email to email@example.com. Questions can be sent in now or during the presentation.